



HEDIS[®] Measures Overview for Behavioral Health Providers



Behavioral Health HEDIS® Measures Overview

The National Committee for Quality Assurance (NCQA®) has developed measures of health care that are quantifiable, comparable, and meaningful. They are called the Healthcare Effectiveness Data and Information Set (HEDIS®) measures. NCQA reports that, “HEDIS is one of health care’s most widely used performance improvement tools”.

“191 million people are enrolled in plans that report HEDIS results” to measure performance on important dimensions of care and service; HEDIS consists of over 90 measures across six domains of care.

Stemming from the measures set forth by HEDIS, the Centers for Medicare and Medicaid Services (CMS) deployed its 5-Star Plan rating system that effectively rates a health plan’s Medicare Advantage programs. Ratings emphasize patient care and satisfaction, using national clinical and service-quality measures (HEDIS), health outcomes and patient feedback. Though the behavioral health HEDIS measures are not yet a part of the CMS rating system, they may be in the future.

- We work in collaboration with our health plan customers to design activities to improve our health plans’ HEDIS rates. We can only do this in coordination with your efforts to provide good clinical care of our patients.
- Improvement in HEDIS measures demonstrates that patients are experiencing better clinical outcomes.

How is HEDIS Relevant to My Practice?

HEDIS offers a clear standardized measure of clinical outcome that is used throughout the entire health care industry. It allows us to identify the impact of clinical interventions across a population of health plan members.

What is Your Role in HEDIS?

You and your office staff can help facilitate the HEDIS process improvement by:

- Understanding and adhering to the best practice recommendations for each of the HEDIS measures
- Providing appropriate care within the designated timeframes
- Documenting all care in the patient’s medical record
- Accurately coding all claims

Behavioral Health HEDIS® Measures Overview

Measure Name	Description	Tips for Success
Measures related to common behavioral health disorders		
<p>Antidepressant Medication Management (AMM)</p>	<p>The percentage of members 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression and who remained on an antidepressant medication treatment. Two rates are reported:</p> <ul style="list-style-type: none"> • <i>Effective Acute Phase Treatment.</i> The percentage of members who remained on an antidepressant medication for at least 84 days (12 weeks) • <i>Effective Continuation Phase Treatment.</i> The percentage of members who remained on an antidepressant medication for at least 180 days (6 months) 	<p>This measure focuses on medication adherence for patients taking antidepressants.</p> <p>Screening:</p> <ul style="list-style-type: none"> • Screening tools (e.g., PHQ-9) may provide objective assessment and better identify who would or would not benefit from medication • Screening tools are available at Providerexpress.com. Go to Clinical Resources - Clinical Tools and Quality Measures Toolkit • Encourage patients to accept a referral for psychotherapy and help them understand that mental health diagnoses are medical illnesses, not character flaws or weaknesses • Encourage patients to actively engage in a discussion about their expectations of treatment and review their treatment plan prior to starting medication <p>After New Prescription:</p> <ul style="list-style-type: none"> • Inform patients that it may take up to 12 weeks for full effectiveness of medication and discuss side effects and the importance of medication adherence • Encourage patients to make an appointment, in-person or using telemental health/virtual visits, with you if they have any questions or are considering stopping a medication



Behavioral Health HEDIS® Measures Overview

Measure Name	Description	Tips for Success
Measures related to common behavioral health disorders		
<p>Follow-Up Care for Children Prescribed ADHD Medication (ADD)</p>	<p>The percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed. Two rates are reported:</p> <ul style="list-style-type: none"> • Initiation Phase. A follow-up visit with practitioner with prescribing authority during the 30-day Initiation Phase • Continuation and Maintenance (C&M) Phase: Children who remained on the ADHD medication and have at least two follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended 	<p>This measure focuses on follow-up care after patients are prescribed an ADHD medication.</p> <p>Screening:</p> <ul style="list-style-type: none"> • Screening/assessment tools (e.g., Vanderbilt Scales) may assist in diagnosing ADHD • Screening tools are available at Providerexpress.com. Go to Clinical Resources - Clinical Tools and Quality Measures Toolkit <p>After New Prescription:</p> <ul style="list-style-type: none"> • Schedule a return appointment with prescriber within 30 days of initial ADHD prescription start date • Continue to monitor patients, with two more visits in the next 9 months • Appointments may be in person or using telemental health/virtual visits



Behavioral Health HEDIS® Measures Overview

Measure Name	Description	Tips for Success
Measures related to common behavioral health disorders		
<p>Initiation and Engagement of Substance Use Disorder Treatment (IET)</p>	<p>The percentage of adolescent and adult members with a new substance use disorder (SUD) episode who received the following:</p> <ul style="list-style-type: none"> • <i>Initiation of SUD Treatment.</i> Treatment through an inpatient SUD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis • <i>Engagement of SUD Treatment.</i> Patients who initiated treatment and who had two or more additional services with a diagnosis of SUD within 34 days of the initiation visit 	<p>This measure focuses on follow-up treatment when diagnosing a patient with substance use disorder.</p> <p>Screening:</p> <ul style="list-style-type: none"> • Screening Tools (e.g., SBIRT, AUDIT-PC, CAGE-AID, CUDIT-R) may assist in the assessment of substance use and can be a useful tool to aid in discussing motivation for treatment • Screening tools are available at Providerexpress.com. Go to Clinical Resources - Clinical Tools and Quality Measures Toolkit • “Unspecified use” diagnosis codes should be used sparingly <p>After Diagnosis:</p> <ul style="list-style-type: none"> • Patients who are newly diagnosed with a substance use disorder should be seen within 14 days to assess their ability to reduce or abstain from the substance(s). Schedule follow-up appointments prior to the patient leaving your office • Ensure the patient has two more visits within the next 34 days • Reach out to patients if they do not attend their appointments • Appointments may be in person to using telehealth/telemental health/virtual visits • Although community supports such as AA and NA are beneficial, they do not take the place of professional treatment • Encourage newly diagnosed patients to engage in treatment by assisting them in identifying their own motivation for change and their own goals for recovery • Obtain a release of information (ROI) to involve your patient’s family and support systems, as well as other medical or behavioral health practitioners



Behavioral Health HEDIS® Measures Overview

Measure Name	Description	Tips for Success
Measures related to follow up after receiving higher levels of care		
<p>Follow-Up After Hospitalization for Mental Illness (FUH)</p>	<p>The percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental illness diagnoses and who had an outpatient visit, an intensive outpatient encounter or partial hospitalization with a mental health practitioner. Two rates are reported:</p> <ul style="list-style-type: none"> • Follow-up within 7 days of discharge • Follow-up within 30 days of discharge 	<p>This measure focuses on follow-up treatment: this must be with a behavioral health practitioner.</p> <ul style="list-style-type: none"> • When one of your patients is discharged from an inpatient mental health stay, make every effort to schedule their follow-up appointment within 7 days • Patients receiving medication from a medical practitioner still need post-discharge supportive therapy with a licensed behavioral health practitioner such as a therapist or social worker • Reach out to patients to reschedule missed follow-up appointments • If a situation arises where a patient is unable to be seen within 7 days, ensure they have an appointment within 30 days of discharge • Appointments may be in person or using telehealth/telemental health/virtual visits
<p>Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)</p>	<p>The percentage of acute inpatient hospitalizations, residential treatment, or detoxification visits for a diagnosis of substance use disorder (SUD) among members 13 years of age and older that result in a follow-up visit or service for substance use disorder. Two rates are reported:</p> <ul style="list-style-type: none"> • Follow-up for SUD within the 7 days after the visit or discharge • Follow-up for SUD within the 30 days after the visit or discharge 	<p>This measure focuses on follow-up treatment with a medical or behavioral health practitioner.</p> <ul style="list-style-type: none"> • Schedule patients to be seen within 7 days of discharge, for follow-up regarding their substance use, and use substance use diagnosis codes • Reach out to patients to reschedule missed follow-up appointments • If a situation arises where a patient is unable to be seen within 7 days, ensure they have an appointment within 30 days of discharge • Appointments may be in person or using telehealth/telemental health/virtual visits



Behavioral Health HEDIS® Measures Overview

Measure Name	Description	Tips for Success
Measures related to follow up after receiving higher levels of care		
<p>Follow-up After Emergency Department Visit for Mental Illness (FUM)</p>	<p>The percentage of emergency department (ED) visits for members 6 years of age and older with a principal diagnosis of mental illness, who had a follow-up visit for mental illness. Two rates are reported:</p> <ul style="list-style-type: none"> • Follow-up within 30 days of the ED visit • Follow-up within 7 days of the ED visit 	<p>This measure focuses on follow-up treatment with a medical or behavioral health practitioner.</p> <ul style="list-style-type: none"> • Schedule patients to be seen within 7 days of the ED visit, for follow-up regarding their mental health needs, and use mental health diagnosis codes • Reach out to patients to reschedule missed follow-up appointments • If a situation arises where a patient is unable to be seen within 7 days, ensure they have an appointment within 30 days of discharge • Appointments may be in person or using telehealth/telemental health/virtual visits
<p>Follow-up After Emergency Department Visit for Substance Use (FUA)</p>	<p>The percentage of emergency department (ED) visits for members 13 years of age and older with a principal diagnosis of substance use disorder (SUD) or any diagnosis of drug overdose, who had a follow up visit for SUD. Two rates are reported:</p> <ul style="list-style-type: none"> • Follow-up within 30 days of the ED visit • Follow-up within 7 days of the ED visit 	<p>This measure focuses on follow-up treatment with a medical or behavioral health practitioner.</p> <ul style="list-style-type: none"> • Schedule patients to be seen within 7 days of the ED visit, for follow-up regarding their substance use, and use substance use diagnosis codes • Reach out to patients to reschedule missed follow-up appointments • If a situation arises where a patient is unable to be seen within 7 days, ensure they have an appointment within 30 days of discharge • Appointments may be in person or using telehealth/telemental health/virtual visits



Behavioral Health HEDIS® Measures Overview

Measure Name	Description	Tips for Success
Measures related to patients with Schizophrenia and/or those prescribed antipsychotics		
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	The percentage of members 18–64 years of age with schizophrenia, schizoaffective disorder, or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.	<p>This measure focuses on appropriate monitoring for patients with schizophrenia or bipolar disorder and who are taking antipsychotic medication.</p> <ul style="list-style-type: none"> • If you have prescribed antipsychotic medication for your patient, complete screening for diabetes (HbA1c or blood glucose) annually • Educate patients on medication and diagnosis risk factors and why it is important to have annual screenings • Obtain a release of information (ROI) to involve the patient's family and support systems, as well as other medical or behavioral health practitioners
Diabetes Monitoring for People with Diabetes and Schizophrenia (SMD)	The percentage of members 18–64 years of age with schizophrenia or schizoaffective disorder and diabetes who had both an LDL-C test and an HbA1c test during the measurement year.	<p>This measure focuses on diabetes monitoring for patients with schizophrenia or schizoaffective disorder and diabetes.</p> <ul style="list-style-type: none"> • Complete HbA1c and LDL-C screening annually • Educate patients on why it is important to have annual screenings • Obtain a release of information (ROI) to involve the patient's family and support systems, as well as other medical or behavioral health practitioners
Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia (SMC)	The percentage of members 18–64 years of age with schizophrenia or schizoaffective disorder and cardiovascular disease, who had an LDL-C test during the measurement year.	<p>This measure focuses on cardiovascular disease monitoring for patients with schizophrenia or schizoaffective disorder and cardiovascular disease.</p> <ul style="list-style-type: none"> • Complete LDL-C screening annually • Educate patients on why it is important to have annual screenings • Obtain a release of information (ROI) to involve the patient's family and support systems, as well as other medical or behavioral health practitioners



Behavioral Health HEDIS® Measures Overview

Measure Name	Description	Tips for Success
Measures related to patients with Schizophrenia and/or those prescribed antipsychotics		
<p>Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)</p>	<p>The percentage of members 18 and older during the measurement year with schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80% of their treatment period.</p>	<p>This measure focuses on medication adherence for patients taking antipsychotics.</p> <ul style="list-style-type: none"> • Encourage patients to take medications as prescribed • Discuss side effects and encourage patients to reach out to you if they have any questions or are considering stopping a medication • Offer tips to patients, such as: take medication at the same time each day, use a pill box, and enroll in a pharmacy automatic refill program • Consider prescribing long-acting injectable medication (LAIs), if appropriate • Obtain a release of information (ROI) to involve the patient's family and support systems, as well as other medical or behavioral health practitioners



Behavioral Health HEDIS® Measures Overview

Measure Name	Description	Tips for Success
Measures related to patients with Schizophrenia and/or those prescribed antipsychotics		
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	The percentage of children and adolescents 1–17 years of age who had two or more antipsychotic prescriptions and had metabolic testing. (Glucose or HbA1C and LDL–C or other cholesterol test).	<p>This measure focuses on glucose and cholesterol monitoring for children taking antipsychotics medications.</p> <ul style="list-style-type: none"> • Complete an annual blood glucose or HbA1C and LDL –C or other cholesterol tests annually • Educate patients and caregivers on the importance of annual screening • Obtain a release of information (ROI) to involve the patient's family and support systems, as well as other medical or behavioral health practitioners
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	The percentage of children and adolescents 1–17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment.	<p>This measure focuses on children and adolescents who are prescribed antipsychotic medications without a diagnosis of Bipolar Disorder, Schizophrenia, or other Psychotic Disorders.</p> <ul style="list-style-type: none"> • Ensure a psychosocial care appointment occurs at least 90 days prior to prescribing medication or within 30 days of starting an initial prescription for non-psychotic conditions, such as attention deficit disorder and disruptive behaviors • Psychosocial care (interventions) includes structured counseling, case management, care-coordination, psychotherapy and relapse prevention



Behavioral Health HEDIS® Measures Overview

Measure Name	Description	Tips for Success
Measures related to patients with Schizophrenia and/or those prescribed antipsychotics		
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	The percentage of members 18 and older during the measurement year with schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80% of their treatment period.	<p>This measure focuses on medication compliance.</p> <ul style="list-style-type: none"> Encourage patients to take medications as prescribed. Discuss potential side effects with your patients. Offer tips to patients such as: take medication at the same time each day, use a pill box, and enroll in a pharmacy automatic refill program.
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	The percentage of children and adolescents 1–17 years of age who had two or more antipsychotic prescriptions and had metabolic testing. (Glucose or HbA1C and LDL–C or other cholesterol test)	<p>This measure focuses on appropriate monitoring for children with prescribed antipsychotic medications.</p> <ul style="list-style-type: none"> Encourage patients to schedule an annual glucose or HbA1C and LDL-C or other cholesterol test. Assist caregivers in understanding the importance of annual screening.
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	The percentage of children and adolescents 1–17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment.	<p>The measure focuses on children and adolescents who are prescribed antipsychotic medications and yet do not have a diagnosis of Bipolar Disorder, Schizophrenia or other Psychotic Disorders.</p> <ul style="list-style-type: none"> Ensure children and adolescents receive psychosocial treatments prior to or in conjunction with prescribing antipsychotic medication for non-psychotic conditions such as attention deficit disorder and disruptive behaviors. Ensure a psychosocial care appointment occurs at least 90 days prior to prescribing medication or within 30 days of starting an initial prescription for non-psychotic conditions such as attention deficit disorder and disruptive behaviors. Psychosocial treatments (interventions) include structured counseling, case management, care-coordination, psychotherapy and relapse prevention.



Behavioral Health HEDIS® Measures Overview

Measure Name	Description	Tips for Success
Measures related to Opioid Use		
Pharmacotherapy for Opioid Use disorder (POD)	The percentage of new opioid use disorder (OUD) pharmacotherapy events with OUD pharmacotherapy for 180 or more days among members 16 years of age and older with a diagnosis of OUD.	<p>This measure focuses on medication adherence for patients using Medication for Opioid Use Disorder (MOUD), previously referred to as Medication Assisted Treatment (MAT)</p> <ul style="list-style-type: none"> • Encourage patients who begin MOUD/MAT to continue their treatment regimen • Discuss with patients the benefits and risks of treatment with and without medication • Use motivational interviewing to help patients identify their own reasons for change • Encourage patients to speak with you if they have any questions, concerns or are considering stopping the medication • Encourage patients to sign a release of information (ROI) to involve the patient's family and support systems, as well as other medical or behavioral health practitioners



Optum

Optum is a registered trademark of Optum, Inc. in the U.S. and other jurisdictions. All other brand or product names are the property of their respective owners. Because we are continuously improving our products and services, Optum reserves the right to change specifications without prior notice. Optum is an equal opportunity employer.

© 2023 Optum, Inc. All rights reserved.